Regorafenib in Patients with Antiangiogenic-Na ïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase 2b Trial.
CONCLUSION: These findings support the antitumor activity of regorafenib in antiangiogenic-naïve patients with chemotherapy-refractory mCRC.
IMPLICATIONS FOR PRACTICE: The multikinase inhibitor regorafenib improved overall survival in the phase 3 CORRECT and CONCUR trials in heavily pretreated patients with treatment-refractory metastatic colorectal cancer (mCRC). Exploratory subgroup analysis from CONCUR suggested that regorafenib treatment prior to targeted therapy (including bevacizumab) may improve outcomes. In this single-center, single-arm phase 2b study, regorafenib demonstrated antitumor activity in 59 antiangiogenic-naïve patients with chemotherapy-refractory mCRC. Further studies should assess the efficacy of regorafenib in this patient population, as well as explore the reasons behind improved outcomes among patients who had a metabolic response and those who developed hand-foot skin reaction.
PMID: 31175167 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Riechelmann RP, Leite LS, Bariani GM, Glasberg J, Rivelli TG, da Fonseca LG, Nebuloni DR, Braghiroli MI, Queiroz MA, Isejima AM, Kappeler C, Kikuchi L, Hoff PM Tags: Oncologist Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Hypertension | Skin | Study